Logo image of SHAC

SCP & CO HEALTHCARE ACQUIS-A (SHAC) Stock Fundamental Analysis

NASDAQ:SHAC - Nasdaq - US7840651043 - Common Stock - Currency: USD

10.0767  +0.02 (+0.17%)

Fundamental Rating

1

Taking everything into account, SHAC scores 1 out of 10 in our fundamental rating. SHAC was compared to 0 industry peers in the Unkown industry. The financial health of SHAC is average, but there are quite some concerns on its profitability. SHAC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SHAC had positive earnings in the past year.
In the past year SHAC has reported a negative cash flow from operations.
SHAC Yearly Net Income VS EBIT VS OCF VS FCFSHAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 0 2M 4M 6M 8M

1.2 Ratios

Industry RankSector Rank
ROA 4.34%
ROE 4.52%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SHAC Yearly ROA, ROE, ROICSHAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 0 1 2 3 4

1.3 Margins

SHAC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SHAC Yearly Profit, Operating, Gross MarginsSHAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021

More info and screens

5

2. Health

2.1 Basic Checks

SHAC has more shares outstanding than it did 1 year ago.
There is no outstanding debt for SHAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SHAC Yearly Shares OutstandingSHAC Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 5M 10M 15M 20M 25M
SHAC Yearly Total Debt VS Total AssetsSHAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 18.10 indicates that SHAC is not in any danger for bankruptcy at the moment.
SHAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.1
ROIC/WACCN/A
WACCN/A
SHAC Yearly LT Debt VS Equity VS FCFSHAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

SHAC has a Current Ratio of 1.66. This is a normal value and indicates that SHAC is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.66 indicates that SHAC should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
SHAC Yearly Current Assets VS Current LiabilitesSHAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 500K 1M 1.5M

More info and screens

0

3. Growth

3.1 Past

SHAC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.38%.
EPS 1Y (TTM)-46.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-77.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 28.79 indicates a quite expensive valuation of SHAC.
SHAC is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.29, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 28.79
Fwd PE N/A
SHAC Price Earnings VS Forward Price EarningsSHAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SHAC Per share dataSHAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SHAC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCP & CO HEALTHCARE ACQUIS-A

NASDAQ:SHAC (12/9/2022, 8:08:38 PM)

10.0767

+0.02 (+0.17%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.04%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap289.71M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 28.79
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)0.35
EY3.47%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS7.75
TBVpS7.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.34%
ROE 4.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 18.1
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-77.35%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-31.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A